2023-03-13 18:18:39 ET
- Amylyx Pharmaceuticals ( NASDAQ: AMLX ) has risen 20% in after-hours trading after posting Q4 2022 results that beat on the. top and bottom lines.
- Although the company had revenue in the quarter compared to the prior-year period thanks to the launch of ALS therapy Relyvrio and Albrioza (sodium phenylbutyrate and taurursodiol), its net loss widened year over year. In 2022, the company recorded $22.2M in revenue from the drugs in the U.S. and Canada.
- In Q4, Amylyx's ( AMLX ) net loss rose to ~$42.7M from ~$28.3M in the prior-year period. However, on a per share basis, it declined (-$0.65 basic and diluted vs. -$4.10).
- Read why Seeking Alpha contributor Avisol Capital Partners in February upgraded its Amylyx ( AMLX ) rating to buy from hold.
For further details see:
Amylx Pharmaceuticals jumps 20% on Q4 top and bottom line beats